AYLA Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Wilmington, DE.

As of 10/15/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  05/08/2020
Outstanding shares:  13,242,834
Average volume:  29,839
Market cap:   $132,560,768
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -3.56
PB ratio:   3.03
PS ratio:   39.02
Return on equity:   -87.10%
Net income %:   -1,096.41%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy